Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics.

ABSTRACT:

Introduction

Sepsis is characterized by life-threatening organ dysfunction caused by dysregulated host response to infection. A key contributor is the disruption of neutrophil-endothelial interactions. Despite extensive research, there are no FDA-approved therapies that directly target altered neutrophil function in sepsis.

Methods

We previously identified three functionally distinct neutrophil phenotypes in sepsis patients: Hyperimmune, Hypoimmune, and Hybrid, using clinical profiling, organ-on-chip models, and proteomics. In this study, we applied bioinformatics tools to elucidate the molecular pathways and druggable targets associated with each phenotype. Differentially expressed proteins were identified using ExpressAnalyst, while pathway enrichment and modeling were per

SUBMITTER: Langston JC 

PROVIDER: S-EPMC12391923 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature